Introduction
Every year, more than 1 million women worldwide are diagnosed with breast cancer, a disease that accounts for almost a quarter of all female cancers. [1] The highest incidence of breast cancer is in developed countries, with more than 360 000 new cases a year in Europe, and more than 200 000 new cases a year in the USA. [1] Although the worldwide incidence of breast cancer continues to rise, perhaps partly as a result of improved screening programmes, mortality rates are beginning to fall because of earlier detection and advances in treatment. At present, 5-year overall survival for women diagnosed with breast cancer is around 75%. [1] Adjuvant hormonal therapy for hormone-sensitive breast cancer has been one of the most important additions to the treatment of breast cancer, resulting in impressive reductions in the breast cancer recurrence and mortality rates. [2, 3] These oral therapies include either tamoxifen and/or an aromatase inhibitor and are typically prescribed for 5 years or longer. Surprisingly, despite the dramatic efficacy of hormonal agents, there is increasing evidence that the early discontinuation and non-adherence rates for both tamoxifen and aromatase inhibitors are high and often unrecognized. [4] [5] [6] [7] [8] [9] [10] [11] Expert group of oncologist meet in the update in oncology-X-2017 to discuss on available strategies and duration of adjuvant hormonal therapy in treatment of breast cancer.
The update in oncology-X-2017 was organized by Sir Ganga Ram Hospital group met to discuss and arrive at a consensus statement to provide community oncologists practical guidelines for challenging common case scenarios in Breast Cancer out of these we are discus about duration of adjuvant hormonal therapy in breast cancer in this chapter. This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
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One of the most dramatic and important additions to the treatment of breast cancer has been adjuvant hormonal therapy for hormone-sensitive breast cancer, with impressive reductions in recurrence and mortality. [24, 25] These oral agents include tamoxifen and aromatase inhibitors (AIs) and are typically prescribed for 5 years or longer. Nonetheless, it is surprising to find that, despite the dramatic efficacy of hormonal agents, there is a discontinuation rate of approximately 7% to 10% per year for tamoxifen and AIs. [26] [27] [28] [29] [30] [31] [32] [33] Reports indicate that only 40% to 60% of patients with BC finish their recommended courses of hormonal therapy, despite the fact that randomized trials show higher recurrence rates and worse survival with _ 5 years of treatment. [32, [34] [35] [36] [37] Adjuvant medical therapy for patients with primary breast cancer has led to a substantial reduction in mortality from this disease. [38] However, adjuvant therapy trials to test the many new agents that are in development would require thousands of patients, many years of follow-up and very large resources. In the absence of such trial data, there is an urgent need for biomarkers of efficacy that can reliably predict long-term outcomes. Endocrine treatments for breast cancer appear to act largely by inhibiting tumor cell proliferation. Thus, markers of tumor cell proliferation, such as Ki67, are candidate markers of efficacy that can be evaluated after short-term (e.g., 2 weeks) treatment of primary breast cancer patients, before they undergo surgery.
Tamoxifen is a selective estrogen receptor (ER) modulator that acts (along with its metabolites) largely or wholly by competitive binding to the receptor protein. [39] In the 75% to 80% of patients with early breast cancer who have ER-positive disease, treatment with 5 years of tamoxifen immediately and substantially reduces local, contralateral, and distant recurrence rates and reduces 15-year breast cancer mortality, with little effect on the aggregate of all other causes of death. [40, 41] However, there is little or no effect on breast cancer outcomes in ER-negative disease. The early results from the first clinical trials of tamoxifen showed only a small absolute gain in 5-year survival, 3 but the additional mortality reductions during years 5 to 9 and 10 to 14 were each about as great as the mortality reduction during years 0 to 4 (the 5 years while tamoxifen was still being taken). [40] Hence, the absolute reduction in breast cancer mortality produced by 5 years of tamoxifen was almost three times as great 15 years after diagnosis as it had been only 5 years after diagnosis.
For more than 20 years, the anti-oestrogen tamoxifen has been the established endocrine djuvant therapy after surgery for postmenopausal women with early breast cancer. 5 years is generally judged the optimum duration for treatment, [41] since tamoxifen therapy beyond 5 years seems to confer no extra benefit in terms of disease-free survival. [42, 43] However, several side effects are inherent with long-term tamoxifen treatment. The partial oestrogenic activity of tamoxifen in some tissues leads to an increased risk of endometrial cancer and thromboembolic events over the course of treatment. [44] [45] [46] Tamoxifen resistance can also develop. [47] The 5-year standard for adjuvant tamoxifen therapy, therefore, seems to be imposed by the limitations of the drug rather than by the optimum duration of therapy. In particular, the relapse pattern for low-risk and intermediate-risk tumours indicates that adjuvant treatment should continue after 5 years, with overview results suggesting that there is a 1·5-2% yearly risk of recurrence of breast cancer in years 5-15 after initial diagnosis. [48, 49] The 15-year outcome of some oestrogen-receptor positive tumours might be worse than that of oestrogen receptor negative lesions. [50] The administration of tamoxifen beyond the optimum time of efficacy might, therefore, result in side-effects without a concomitant therapeutic benefit.
The limitations of tamoxifen have led to a search for alternative endocrine therapies with increased efficacy and fewer long-term complications. The thirdgeneration aromatase inhibitors anastrozole, letrozole, and exemestane are highly selective for aromatase and inhibit 97-99% of oestrogen synthesis from this source. [51, 52] Results of trials such as the ATAC study [53] have shown the improved efficacy and tolerability of anastrozole over tamoxifen, and data now support the use of 5 years' anastrozole as adjuvant therapy for postmenopausal women with early breast cancer. However, tamoxifen is still a useful and ubiquitous treatment option, and by employing a strategy of switching therapy from tamoxifen to an aromatase inhibitor, the unnecessary longer-term side-effects of tamoxifen might be obviated and the complications of long-term tamoxifen therapy avoided. Data indicate a positive effect on recurrence-free survival when switching from tamoxifen to an aromatase inhibitor. [54, 55] The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial, [56] showed that initial adjuvant treatment of postmenopausal women with early-stage breast cancer with the third-generation aromatase inhibitor anastrozole was more effi cacious with a better safety profile than tamoxifen. In addition, several studies [57] [58] [59] have shown the benefi ts of switching to anastrozole compared with remaining on tamoxifen for 5 years. The results of the combined analysis [59] of the Arimidex-Nolvadex (ARNO 95) and Austrian Breast and Colorectal Cancer Study Group (ABCSG 8) trials showed that switching postmenopausal women with hormone-sensitive early-stage breast cancer from tamoxifen to anastrozole after 2 years' adjuvant treatment results in a signifi cant improvement in event-free survival compared with those who continued tamox ifen. Results from the original and updated analyses of the Italian Tamoxifen Arimidex (ITA) trial in node-positive women only [57, 58] also showed signifi cant clinical benefi ts from switching to anastrozole after 2-3 years of adjuvant tamoxifen.
The most recent technical assessment from the American Society of Clinical Oncology (ASCO) [60] recommends that optimum adjuvant therapy for postmenopausal women should now include the use of an aromatase inhibitor, either as initial treatment or after 2-5 years' treatment with tamoxifen, to reduce the risk of tumour recurrence. Clearly, third-generation aromatase inhibitors have a key role in management of postmenopausal women with early stage breast cancer, the American Society of Clinical Oncology (ASCO) Technology Assessment recommended that 5 years of tamoxifen alone was no longer the best adjuvant treatment for hormone-sensitive early-stage breast cancer, and that treatment should include use of an aromatase inhibitor to reduce the risk of tumour recurrence. [60] The ASCO assessment favours using the aromatase inhibitor that has been most studied in the setting closest to the individual patient's clinical circumstance.
Conclusion
In conclusion of this discussion switching treatment to an aromatase inhibitor offers the opportunity to continue adjuvant hormonal therapy for longer than 5 years, since problems of tolerability that arise from the partial agonist effects of tamoxifen are circumvented. As per ASCO guidelines recommended treatment of women who have hormone receptor-positive breast cancer and are premenopausal with 5 years of tamoxifen, and those who are postmenopausal a minimum of 5 years of adjuvant therapy with an aromatase inhibitor or tamoxifen followed by an aromatase inhibitor (in sequence). If women are pre-or perimenopausal and have received 5 years of adjuvant tamoxifen, they should be offered 10 years total duration of tamoxifen. If women are postmenopausal and have received 5 years of adjuvant tamoxifen, they should be offered the choice of continuing tamoxifen or switching to an aromatase inhibitor for 10 years total adjuvant endocrine therapy. The optimal timing and duration of endocrine treatment remain unresolved.
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Take Home Message
Case -60 year postmenopausal lady diagnosed with infiltrating duct carcinoma left breast. She undergoes modified radical mastectomy. HPE results -T2N0M0. ER++ve, PR+ve, Her2/Neu-ve. Not willing for Oncotype Dx. She has taken adjuvant chemotherapy followed by hormonal therapy with anastrozole for five years. Now she comes for follow up, is asymptomatic and asks what she should do next 1
Continue anastrozole and add zolendronic acid 2
Continue anastrozole if original disease was single axillary node positive 3
The recommendation remains the same even if the original disease was with multiple axillary lymph node positivity.
